PMA device
Orcel Bilayered Cellular Matrix
Forticell Bioscience · Dressing, Wound And Burn, Interactive (MGR, Class III) · First FDA decision Aug 31, 2001, newest Aug 31, 2001BurnsChronic wounds and ulcers
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
2
Naming "Orcel Bilayered Cellular"
MAUDE reports
0
Brand "Orcel Bilayered Cellular", since 2015
PubMed studies
0
Mentioning "Orcel Bilayered Cellular"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
P010016 · Decided Aug 31, 2001 · 179 days after receipt
Device type: Dressing, wound and burn, interactive (MGR) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Orcel Bilayered Cellular", any status and sponsor, newest update first.
Ortec InternationalNot on our public-company list
NCT00270972 · 60 participants · Start Sep 2005
Device: Bilayered Cellular Matrix (OrCel) · For: Venous Insufficiency; Leg Ulcer
Sites: Montgomery, Alabama; Phoenix, Arizona; Castro Valley, California · 10 sites in all
- Evaluation of Bilayered Cellular Matrix (OrCel) for the Treatment of Venous UlcersPivotal-lookingCompleted
Ortec InternationalNot on our public-company list
NCT00270946 · 130 participants · Start Apr 2002
Device: Bilayered Cellular Matrix (OrCel) · For: Venous Leg Ulcer; Venous Stasis Ulcer
Sites: Montgomery, Alabama
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Orcel Bilayered Cellular", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MGR
11 reports: 1 malfunction, 9 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Orcel Bilayered Cellular"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MGR.
- ApligrafOrganogenesis, Inc. · PMA 2013
- TranscyteShire Regenerative Medicine · PMA 2004
- DermagraftShire Regenerative Medicine · PMA 2012
- Integra Dermal Regeneration TemplateIntegra Lifesciences Corp. · PMA 2017
- Transcyte Human Fibroblast-Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2011
- Apilgraf(Graftskin)Organogenesis, Inc. · PMA 2002
- Transcyte/Human Fibroblast Derived Temporary Skin SubstituteShire Regenerative Medicine · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.